A picture to understand China PD-1/PD-L1 2021.12

From the start of the first year of China's tumor immunity in June 2018 , it took a short period of 3 and a half years to December 12, 2021.

Since the start of the first year of China's tumor immunization in June 2018 , it will take a short period of 3 and a half years to December 12, 2021.

NMPA has approved 11 PD-1/PD-L1 products, involving 11 cancer types and 44 indications

NMPA has approved 11 PD-1/PD-L1 products, involving 11 cancer types , 44 indications, 11 cancer types and 44 indications

It is expected that many PD-1/PD-L1 products will be approved in 2022 , such as CStone, Fuhong, Jiahe, etc.

Is expected in 2022 will have a variety of PD-1 / PD-L1 product is approved, the cornerstone for example, complex macros, and so on Kerry in 2022

Non-small cell lung cancer : MSD, Hengrui, Baekje, Cinda have been approved as first-line squamous cell carcinoma and adenocarcinoma, and AZ is the only company in consolidation treatment
.

Non-small cell lung cancer : MSD, Hengrui, Baekje, Cinda have been approved as first-line squamous cell carcinoma and adenocarcinoma, and AZ is the only company in consolidation treatment
.

Non-small cell lung cancer Non-small cell lung cancer: MSD, Hengrui, Baiji, Cinda have been approved as first-line squamous cell carcinoma and adenocarcinoma, and AZ is the only company in consolidation treatment

Small cell lung cancer : AZ and Roche’s PD-L1 are the only first-line products

Liver cancer : Roche and Cinda are both approved first-line treatment for advanced stage

Esophageal cancer : MSD and Hengrui were approved first-line treatment for advanced stage

Gastric cancer : O drug is currently the only advanced first-line treatment

Nasopharyngeal cancer : Hengrui and Junshi lead the first-line treatment

Head and neck cancer : MSD and BMS are both in the first line

Colorectal cancer : MSD is currently the only first-line treatment for MSI-H

Urothelial cancer : Junshi and Baekje lead, but both are second-line therapies

Melanoma : K drug and Junshi are leading, both are second-line treatments

Hodgkin's lymphoma : the densest, up to 5 types

Leave a message here